Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Category Primary study
JournalCANCER RESEARCH
Year 2017
This article has no abstract
Epistemonikos ID: d2e21561f3ff39d9c65678a453fe2a681d690a35
First added on: Mar 23, 2022